Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus

Study Overview
=================
Brief Summary
-----------------
One of the best understood mechanisms by which cytokines activate signals, thus eliciting specific responses in target cells, involves enzymes such as Janus kinases (JAKs) and transcriptional factors such as signal transducers and activators of transcription (STATs). For immune mediated diseases, both activating and inactivating mutations of JAKs and STATs may cause abnormalities in immune homeostasis. Polymorphisms of JAK/STAT genes have been linked to susceptibility for rheumatoid arthritis (RA) , systemic lupus erythematosus (SLE), psoriatic arthritis (PA) and inflammatory bowel disease (IBD) . Janus_kinase 3 expression will be evaluated in the serum and renal tissue of lupus patients during active stage of the disease through this study

Detailed Description
-----------------
Investigators will assess the relationship between the expression of Janus_kinase 3 and the clinical and laboratory parameters of disease activity . Disease activity will be assessed through the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Also, investigators will evaluate the relationship between Janus_ kinase 3 expression and histopathological classes of lupus nephritis according to the 2003 International Society of Nephrology/ Renal Pathology Society (ISN/RPS) classification of lupus nephritis. This will be done through Janus_kinase 3 assessment in the blood and renal tissue of lupus patients.

Official Title
-----------------
Evaluation of Janus Kinase_3 Expression in Juvenile Onset Systemic Lupus Erythematosus

Conditions
-----------------
Systemic Lupus Erythematosus

Intervention / Treatment
-----------------
* Procedure: renal biopsy and blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age younger than 16 years. Active disease stage Patients with biopsy proven lupus nephritis according to ISN/RPS classification criteria of lupus nephritis Exclusion Criteria: Lupus patients in remission. Lupus patients with end stage renal disease. Lupus patients with secondary thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). patients with moderate or severe infection

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group study 1<br>children and adolescents who diagnosed as lupus patients | Procedure: renal biopsy and blood sampling<br>* renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3<br>|
| group study 2<br>age and sex matched healthy children free from any infection with no family history of immunological diseases | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Janus-kinase 3 expression | evaluation of Janus-kinase 3 expression in blood and renal tissue of lupus patients during active stage of disease | within 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation | relationship between Janus- kinase expression and clinical and laboratory parameters of disease activity | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Janus-kinase3, active, lupus